218 related articles for article (PubMed ID: 11300658)
1. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
Ribstein J; Picard A; Armagnac C; Sissmann J; Mimran A
J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658
[TBL] [Abstract][Full Text] [Related]
2. Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects.
Schmitt F; Martinez F; Brillet G; Nguyen-Khoa T; Brouard R; Sissmann J; Lacour B; Grunfeld JP
J Cardiovasc Pharmacol; 1998 Feb; 31(2):314-21. PubMed ID: 9475275
[TBL] [Abstract][Full Text] [Related]
3. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men.
McIntyre M; MacFadyen RJ; Meredith PA; Brouard R; Reid JL
J Cardiovasc Pharmacol; 1996 Jul; 28(1):101-6. PubMed ID: 8797143
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans.
Belz GG; Butzer R; Kober S; Mutschler E
J Cardiovasc Pharmacol; 2002 Apr; 39(4):561-8. PubMed ID: 11904530
[TBL] [Abstract][Full Text] [Related]
5. SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers.
Hagmann M; Nussberger J; Naudin RB; Burns TS; Karim A; Waeber B; Brunner HR
J Cardiovasc Pharmacol; 1997 Apr; 29(4):444-50. PubMed ID: 9156352
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
[TBL] [Abstract][Full Text] [Related]
7. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade.
Leenen FH; Yuan B
Hypertension; 2001 Mar; 37(3):981-4. PubMed ID: 11244027
[TBL] [Abstract][Full Text] [Related]
8. A pharmacodynamic study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys.
Roccon A; Marchionni D; Donat F; Segondy D; Cazaubon C; Nisato D
Br J Pharmacol; 1994 Jan; 111(1):145-50. PubMed ID: 8012690
[TBL] [Abstract][Full Text] [Related]
9. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects.
Burnier M; Hagman M; Nussberger J; Biollaz J; Armagnac C; Brouard R; Weber B; Brunner HR
Hypertension; 1995 Apr; 25(4 Pt 1):602-9. PubMed ID: 7721404
[TBL] [Abstract][Full Text] [Related]
10. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
Ruilope L
J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I.
Inglessis N; Nussberger J; Hagmann M; Hiesse-Provost O; Insuasty J; Reid J; Ménard J; Brunner HR
J Cardiovasc Pharmacol; 1995 Jun; 25(6):986-93. PubMed ID: 7564346
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects.
Marino MR; Langenbacher K; Ford NF; Uderman HD
J Clin Pharmacol; 1998 Mar; 38(3):246-55. PubMed ID: 9549663
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
[TBL] [Abstract][Full Text] [Related]
14. Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension.
van den Meiracker AH; Admiraal PJ; Janssen JA; Kroodsma JM; de Ronde WA; Boomsma F; Sissmann J; Blankestijn PJ; Mulder PG; Man In 't Veld AJ
Hypertension; 1995 Jan; 25(1):22-9. PubMed ID: 7843749
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the AT(2)-receptor in angiotensin II-induced facilitation of sympathetic neurotransmission.
Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):181-7. PubMed ID: 12563569
[TBL] [Abstract][Full Text] [Related]
16. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
Belz GG; Butzer R; Kober S; Mang C; Mutschler E
Clin Pharmacol Ther; 1999 Oct; 66(4):367-73. PubMed ID: 10546920
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans.
Ohtawa M; Takayama F; Saitoh K; Yoshinaga T; Nakashima M
Br J Clin Pharmacol; 1993 Mar; 35(3):290-7. PubMed ID: 8471405
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism.
Stokes GS; Monaghan JC; Ryan M; Woodward M
J Hypertens; 2001 Jun; 19(6):1161-5. PubMed ID: 11403366
[TBL] [Abstract][Full Text] [Related]
19. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
20. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.
Christen Y; Waeber B; Nussberger J; Porchet M; Borland RM; Lee RJ; Maggon K; Shum L; Timmermans PB; Brunner HR
Circulation; 1991 Apr; 83(4):1333-42. PubMed ID: 2013151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
